Vocal Cord Dysfunction: A Rare but Severe Complication of Tardive Dyskinesia
In this case report, a 65-year-old female presented with chronic obstructive pulmonary disease, major depressive disorder on risperidone, tardive dyskinesia (TD), and dysphagia presented with worsening shortness of breath.
Managing Painless Legs and Moving Toes Syndrome With Individualized Treatment
Painless legs and moving toes syndrome is a rare movement disorder characterized by semi-continuous, involuntary toe movements without associated pain. This report describes a 48-year-old woman with the condition in the context of chronic neuroleptic use.
Expert Insights on Telehealth’s Role and Limitations in Tardive Dyskinesia Management
Telehealth has emerged as a valuable tool in assessing and managing tardive dyskinesia (TD), a movement disorder associated with prolonged use of dopamine receptor-blocking agents.
Video: Differentiating Tardive Dyskinesia From Parkinsonism for Accurate Treatment
In this video, Dr. Craig Chepke underscores the importance of distinguishing tardive dyskinesia (TD) from other movement disorders to ensure proper treatment. While increased awareness of TD is promising, over-diagnosing all abnormal movements as TD can lead to errors.
Instructional Video Highlights the Importance of AIMS Exam for Detecting and Monitoring Tardive Dyskinesia
In this instructional video, Dr. Rakesh Jain, co-chair of Psych Congress, emphasizes the importance of the Abnormal Involuntary Movement Scale (AIMS) in diagnosing and monitoring tardive dyskinesia (TD). Dr. Jain details the components, scoring, and procedure for conducting the AIMS exam.
Understanding the Differences Between Tardive Dyskinesia and Other Movement Disorders
Tardive dyskinesia (TD) is an involuntary movement disorder that develops as a side effect of long-term use of medications that block dopamine receptors, such as antipsychotics.
Early Diagnosis and Treatment Essential for Managing Tardive Dyskinesia and Minimizing Risks
Tardive dyskinesia (TD) is a movement disorder caused by long-term use of dopamine receptor-blocking agents, especially antipsychotics.
Differentiating Lithium-Induced Versus Antipsychotic-Induced Tremors May be Crucial for Treatment
Tremors are neurological conditions marked by rhythmic shaking due to involuntary muscle contractions, which can arise from various causes, including drug use, medical conditions like multiple sclerosis or Parkinson’s disease, and substance abuse. Lithium-induced tremors, a type of postural tremor, are common early in treatment and often present as fine hand tremors, particularly in older patients. Differentiating these from extrapyramidal tremors, caused by antipsychotic medications, is crucial for proper management, as each type has distinct underlying mechanisms and treatment approaches.
Study Finds D1 Receptors Key to Antipsychotic Effectiveness, Paving the Way for Better Schizophrenia Treatments
Scientists at Northwestern Medicine have found that antipsychotic medications’ effectiveness in treating schizophrenia is better predicted by their interaction with D1 dopamine receptor-expressing neurons rather than D2 receptors, challenging existing beliefs. Current antipsychotic drugs, which are widely used but often ineffective for many patients and associated with serious side effects like tardive dyskinesia and parkinsonism, were thought to primarily target D2 receptors. However, this new research indicates that their efficacy is more closely related to their effect on D1 receptors in the brain’s striatum, fundamentally changing the understanding of the neural mechanisms underlying psychosis.
Case Study: Methotrexate-Linked Oromandibular Dystonia in a 70-Year-Old Male
Oromandibular dystonia is a focal dystonia involving involuntary movements of the jaw, lips, tongue, and oropharynx, often affecting speech and eating. The diagnosis is clinical and can be challenging. A 70-year-old male with a history of psoriatic arthritis treated with methotrexate developed oromandibular dystonia, initially diagnosed as Meige’s syndrome. The patient’s condition improved significantly after switching from methotrexate to sulfasalazine and receiving botulinum toxin-A (BoNT-A) injections, suggesting a possible link between methotrexate and the dystonia.
